China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. has announced that its subsidiary, Jiangzhong Pharmaceutical, has released its financial results for the first half of 2024, reporting an 8.66% increase in net profit attributable to shareholders despite an 8.02% decrease in revenue. The company’s total assets and net assets saw a marginal increase, while net cash flow from operating activities declined by 11.99%. These mixed results highlight the company’s profitability in a challenging period, with an improved net profit margin and basic earnings per share rising to 0.78 RMB.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.